Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Trial of Individual Psychosocial Interventions for Cancer Patients

Completed

Conditions: Advanced Solid Tumor Diseases

Interventions: Behavioral: standard Individual Supportive Psychotherapy (ISP)
Behavioral: Individual Meaning-Centered Psychotherapy (IMCP)
Behavioral: enhanced usual care (EUC)

First Posted Date: 2011-03-25

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 346

Registration Number: NCT01323309

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Randomization to No Panitumumab
Drug: panitumumab

First Posted Date: 2011-03-11

Last Posted Date: 2024-07-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT01312857

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 5 locations

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Completed

Conditions: Lung Cancer

Interventions: Genetic: obtain tissue specimens

First Posted Date: 2011-02-21

Last Posted Date: 2021-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01300429

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI

Withdrawn

Conditions: Breast Cancer

Interventions: Other: MRI

First Posted Date: 2011-02-16

Last Posted Date: 2012-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT01297231

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin
Drug: BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)
Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin
Drug: BKM120, Paclitaxel + Carboplatin

First Posted Date: 2011-02-16

Last Posted Date: 2017-03-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT01297452

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Phase 1

Completed

Conditions: Relapsed/Refractory Sarcomas
Solid Tumors

Interventions: Drug: Vorinostat and Etoposide

First Posted Date: 2011-02-11

Last Posted Date: 2021-11-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT01294670

Locations: 🇺🇸
All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: pertuzumab in combination with trastuzumab and paclitaxel

First Posted Date: 2011-01-13

Last Posted Date: 2020-08-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 70

Registration Number: NCT01276041

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 3 locations

Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls
Behavioral: Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction

First Posted Date: 2011-01-12

Last Posted Date: 2019-07-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 99

Registration Number: NCT01275404

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: STA-9090

First Posted Date: 2011-01-11

Last Posted Date: 2015-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT01273896

Locations: 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Early Phase 1

Active, not recruiting

Conditions: Non-Hodgkin's Lymphoma
Myeloma
Active Solid Malignancy

Interventions: Drug: PET Imaging using 124 IPUH71

First Posted Date: 2011-01-04

Last Posted Date: 2025-01-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 63

Registration Number: NCT01269593

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy